After a median follow-up of 38.2 months, women with HER2-low breast cancer had significantly longer median OS than those with HER2-zero breast cancer (HER2-Low: 37.1 months vs. HER2-Zero: 31.7 months; log-rank p < 0.001). This evidence concerns the gene ERBB2 and breast carcinoma.